M3 Wake Research acquires Clinical Research Center of Nevada (CRCN)
Renowned Research Network Expands Operations into Nevada, Adding Expertise in Vaccines, Sleep Disorders, and Pediatric Research
[RALEIGH, NC] – M3 Wake Research, announces the acquisition of Clinical Research Center of Nevada (CRCN), one of the largest clinical research organizations in Nevada, and a leading provider of quality and comprehensive multispecialty clinical research services. This acquisition expands Wake Research’s coast-to-coast coverage of clinical research populations in the United States and encompasses communities of nearly 21 million people.
“This exciting acquisition brings one of the most experienced and recognized sites in the industry into our nationwide network,” stated Ella Grach, MD, President and Chief Executive Officer of Wake Research. “Darlene Steljes and the CRCN team have built a strong, successful operation offering advanced expertise in many specialties with extensive attention to vaccines, sleep disorders, and pediatric research,” she added.
“With its reputation for being patient-focused, and as the ‘go-to site’ for many indications, CRCN will be a key part of our continued research network expansion,” Dr. Grach continued. “Combining forces with CRCN will enable us to provide even greater opportunities for our patients’ health. Together, we will continue meeting the evolving needs of the drug discovery process and closing the gap between clinical research and healthcare by offering clinical trials as a care option.”
M3-Wake Research was originally founded by a large multi-specialty group practice and has conducted clinical research studies since 1989. Today, it is among the largest Phase I-IV clinical trial site service companies in North America. From its corporate office based in the Research Triangle Park area of Raleigh, NC, M3-Wake Research has built a combined database of more than 950,000 subjects to date, with an integrated network of 16 research sites operating in seven states: Alabama, Arizona, California, Georgia, North Carolina, Tennessee, and Texas. Their board-certified physicians have completed more than 7,100 successful clinical trials in most major therapeutic areas, with particular expertise in gastroenterology, neuroscience, dermatology, endocrinology, immunology, and women’s health.
“Along with co-owner Troy Odynski, and the entire CRCN team, I look forward to our future growth as part of M3 Wake Research and their national network of clinical research operations,” states Darlene Steljes, CEO and co-owner of CRCN. “Our patients, providers, and sponsors will benefit immensely from the wealth of additional resources provided by M3-Wake Research.”
Since 1996, CRCN has successfully connected board-certified investigators with clinical trials across a broad range of therapeutic areas. The integration of CRCN into the national network of M3-Wake Research adds six investigator sites and more than 100,000 potential subjects, and enables the existing CRCN network to benefit from M3 Wake’s industry-leading infrastructure including centralized patient recruitment and retention, a company-wide QA/QC program, an in-house training program, and marketing and advertising services. M3 Wake Research builds upon the success of a fully integrated and dedicated research site model. Further, by leveraging centralized marketing and advertising services, a call center, accelerated patient engagement program, and the individual successes of each site, efficiencies have increased exponentially, as recognized by many sponsors already.
With this acquisition, CRCN joins the family of M3 USA brands including: MDLinx, a clinical education and medical news website; The Medicus Firm, a physician and advanced practitioner recruiting firm; and PracticeMatch, which provides healthcare employers with the nation’s largest physician recruitment marketing resource. No further financial details of the transaction were made publicly available at this time.
About M3 Inc.:
M3 Inc. operates in the US, Asia, and Europe with over 4 million physician members globally via its physician websites such as mdlinx.com, m3.com, research.m3.com, doctors.net.uk, medigate.net and medlive.cn. M3 Inc. is a publicly traded company on the Tokyo Stock Exchange (TYO:2413) with subsidiaries in major markets including USA, UK, Japan, S. Korea, and China. M3 Inc. provides services to healthcare and the life science industry. In addition to market research, these services include medical education, ethical drug promotion, clinical development, job recruitment, and clinic appointment services. M3 has offices in Tokyo, Washington D.C., Fort Washington, PA, Oxford, London, Beijing, and Seoul.
About M3-Wake Research, Inc.:
M3-Wake Research is an organization of integrated investigational sites, committed to excellence, working closely with and meeting the needs of the biopharmaceutical, biotechnology, medical device and pharmaceutical industries. M3-Wake Research’s 16 sites are fully equipped to meet the needs of sponsors and CROs in the conduct of Phase I-IV clinical trials in a large variety of indications.
M3-Wake Research is known for effectively combining strategic volunteer recruitment, rapid trial start-up and subject enrollment/retention with high-quality clinical trial conduct using standardized operating procedures and centralized marketing and advertising. M3-Wake Research sites have conducted more than 7,000 research studies for hundreds of pharmaceutical and biotech sponsors and CROs. Wake Research’s mission is to bring novel medications, biologics and devices through clinical research to as many people as possible while providing unparalleled service and exceptional value to clinical trial partners and stakeholders.